BiotechTubeBiotechTube
Home/SIGA Technologies/Julie M. Kane
JM

Julie M. Kane

Director

SIGA Technologies

Therapeutic Areas

Infectious DiseaseBiodefensePublic Health Preparedness

SIGA Technologies Pipeline

DrugIndicationPhase
TPOXX (tecovirimat) OralHuman Smallpox DiseaseApproved
TPOXX (tecovirimat) IVHuman Smallpox DiseaseApproved
TPOXX (tecovirimat)Complications from Vaccinia VaccinationPhase 3
Next-Generation Orthopoxvirus InhibitorsOrthopoxvirus InfectionsPre-clinical

Leadership Team at SIGA Technologies

DJ
Daniel J. Luckshire
Chief Executive Officer and Chairman of the Board
DE
Dennis E. Hruby
Chief Scientific Officer
D(
Dieter (DJ) J. Weinand
Lead Independent Director
JJ
James J. Antal
Director
GJ
Gary J. Nabel
Director
HL
Holly L. Phillips
Director
JL
Jaymie L. Durnan
Senior Vice President, Product Development & Manufacturing
MT
Michael T. Klemba
Vice President, Discovery Research
TH
Todd H. Davies
Vice President, Business Development & Government Affairs
View full SIGA Technologies profile